Hector A. Miranda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hector A. Miranda has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas S. Heaton
Department of Molecular Genetics and Microbiology, Duke University School of Medicine
4 shared publications - Andrew N. Macintyre
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27705, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27705, USA
2 shared publications - Kaitlyn N. Burke
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA
2 shared publications - M. Ariel Spurrier
Department of Molecular Genetics and Microbiology, Duke University School of Medicine
2 shared publications - Zhaochen Luo
Department of Molecular Genetics and Microbiology, Duke University School of Medicine
2 shared publications - Benjamin S. Chambers
Affiliation Department of Molecular Genetics and Microbiology Duke University School of Medicine Durham, North Carolina, United States of America
1 shared publication
Latest Publications
- Open Access
- 3 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (10)
FUT1- and GAL3ST2-mediated cellular glycan remodeling broadly restricts sialic acid–dependent viral infections
Sialic acid is an abundant terminal glycan found on the surface of almost all mammalian cells and is utilized by many viruses as an attachment factor and/or bona fide receptor. Altering canonical cellular glycosylation can affect the ability of viruses to initiate infections; however, no systematic analysis of the effects of altering expression of glycan “capping” enzymes on viral infection rates has been previously performed. We therefore designed an arrayed CRISPR activation screen that targeted 54 glycosyltransferases known to perform terminal glycan modifications and then examined the susceptibility of 12 different viruses that rely on sialic acid receptors on the resultant cell lines. We identified two glycosyltransferases, fucosyltransferase 1 (FUT1) and galactose-3-O-sulfotransferase 2 (GAL3ST2), as capable of inhibiting a broad range of viruses when upregulated, including influenza viruses, respiroviruses, paramyxoviruses, enteroviruses, and coronaviruses. Lectin and viral particle binding assays revealed that the fucosylation and sulfation mediated by FUT1 and GAL3ST2 reduced availability of cell surface expressed α2-3 and α2-6 sialylation and impaired viral attachment during the initial entry process. Furthermore, through adeno-associated virus delivery, we confirmed the inhibitory effects of FUT1 and GAL3ST2 on influenza viruses in various cell models, including primary differentiated human airway cells. Together, our findings identify FUT1 and GAL3ST2 as host restriction factors and suggest that their therapeutic dysregulation may represent a broad-spectrum antiviral strategy.
- 3 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (10)
Open AccessFUT1- and GAL3ST2-mediated cellular glycan remodeling broadly restricts sialic acid–dependent viral infections
Sialic acid is an abundant terminal glycan found on the surface of almost all mammalian cells and is utilized by many viruses as an attachment factor and/or bona fide receptor. Altering canonical cellular glycosylation can affect the ability of viruses to initiate infections; however, no systematic analysis of the effects of altering expression of glycan “capping” enzymes on viral infection rates has been previously performed. We therefore designed an arrayed CRISPR activation screen that targeted 54 glycosyltransferases known to perform terminal glycan modifications and then examined the susceptibility of 12 different viruses that rely on sialic acid receptors on the resultant cell lines. We identified two glycosyltransferases, fucosyltransferase 1 (FUT1) and galactose-3-O-sulfotransferase 2 (GAL3ST2), as capable of inhibiting a broad range of viruses when upregulated, including influenza viruses, respiroviruses, paramyxoviruses, enteroviruses, and coronaviruses. Lectin and viral particle binding assays revealed that the fucosylation and sulfation mediated by FUT1 and GAL3ST2 reduced availability of cell surface expressed α2-3 and α2-6 sialylation and impaired viral attachment during the initial entry process. Furthermore, through adeno-associated virus delivery, we confirmed the inhibitory effects of FUT1 and GAL3ST2 on influenza viruses in various cell models, including primary differentiated human airway cells. Together, our findings identify FUT1 and GAL3ST2 as host restriction factors and suggest that their therapeutic dysregulation may represent a broad-spectrum antiviral strategy.
- 20 November 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 209, 211-224
Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza
- 20 November 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 209, 211-224
Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza
- 1 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (745) , eadj4685
Vaccination with antigenically complex hemagglutinin mixtures confers broad protection from influenza disease
Current seasonal influenza virus vaccines induce responses primarily against immunodominant but highly plastic epitopes in the globular head of the hemagglutinin (HA) glycoprotein. Because of viral antigenic drift at these sites, vaccines need to be updated and readministered annually. To increase the breadth of influenza vaccine–mediated protection, we developed an antigenically complex mixture of recombinant HAs designed to redirect immune responses to more conserved domains of the protein. Vaccine-induced antibodies were disproportionally redistributed to the more conserved stalk of the HA without hindering, and in some cases improving, antibody responses against the head domain. These improved responses led to increased protection against homologous and heterologous viral challenges in both mice and ferrets compared with conventional vaccine approaches. Thus, antigenically complex protein mixtures can at least partially overcome HA head domain antigenic immunodominance and may represent a step toward a more universal influenza vaccine.
- 1 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (745) , eadj4685
Vaccination with antigenically complex hemagglutinin mixtures confers broad protection from influenza disease
Current seasonal influenza virus vaccines induce responses primarily against immunodominant but highly plastic epitopes in the globular head of the hemagglutinin (HA) glycoprotein. Because of viral antigenic drift at these sites, vaccines need to be updated and readministered annually. To increase the breadth of influenza vaccine–mediated protection, we developed an antigenically complex mixture of recombinant HAs designed to redirect immune responses to more conserved domains of the protein. Vaccine-induced antibodies were disproportionally redistributed to the more conserved stalk of the HA without hindering, and in some cases improving, antibody responses against the head domain. These improved responses led to increased protection against homologous and heterologous viral challenges in both mice and ferrets compared with conventional vaccine approaches. Thus, antigenically complex protein mixtures can at least partially overcome HA head domain antigenic immunodominance and may represent a step toward a more universal influenza vaccine.
- Open Access
- 27 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009951
Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity
Influenza A viruses encode their genomes across eight, negative sense RNA segments. The six largest segments produce mRNA transcripts that do not generally splice; however, the two smallest segments are actively spliced to produce the essential viral proteins NEP and M2. Thus, viral utilization of RNA splicing effectively expands the viral coding capacity without increasing the number of genomic segments. As a first step towards understanding why splicing is not more broadly utilized across genomic segments, we designed and inserted an artificial intron into the normally nonsplicing NA segment. This insertion was tolerated and, although viral mRNAs were incompletely spliced, we observed only minor effects on viral fitness. To take advantage of the unspliced viral RNAs, we encoded a reporter luciferase gene in frame with the viral ORF such that when the intron was not removed the reporter protein would be produced. This approach, which we also show can be applied to the NP encoding segment and in different viral genetic backgrounds, led to high levels of reporter protein expression with minimal effects on the kinetics of viral replication or the ability to cause disease in experimentally infected animals. These data together show that the influenza viral genome is more tolerant of splicing than previously appreciated and this knowledge can be leveraged to develop viral genetic platforms with utility for biotechnology applications.
- 27 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009951
Open AccessInfluenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity
Influenza A viruses encode their genomes across eight, negative sense RNA segments. The six largest segments produce mRNA transcripts that do not generally splice; however, the two smallest segments are actively spliced to produce the essential viral proteins NEP and M2. Thus, viral utilization of RNA splicing effectively expands the viral coding capacity without increasing the number of genomic segments. As a first step towards understanding why splicing is not more broadly utilized across genomic segments, we designed and inserted an artificial intron into the normally nonsplicing NA segment. This insertion was tolerated and, although viral mRNAs were incompletely spliced, we observed only minor effects on viral fitness. To take advantage of the unspliced viral RNAs, we encoded a reporter luciferase gene in frame with the viral ORF such that when the intron was not removed the reporter protein would be produced. This approach, which we also show can be applied to the NP encoding segment and in different viral genetic backgrounds, led to high levels of reporter protein expression with minimal effects on the kinetics of viral replication or the ability to cause disease in experimentally infected animals. These data together show that the influenza viral genome is more tolerant of splicing than previously appreciated and this knowledge can be leveraged to develop viral genetic platforms with utility for biotechnology applications.